Probiotic normalization of Candida albicans in schizophrenia: A randomized, placebo-controlled, longitudinal pilot study

Highlights • In schizophrenia, elevated Candida yeast antibody levels were lowered by probiotics. • Probiotics compared to placebo also relieved yeast-related bowel discomfort over time. • Candida albicans seropositivity was associated with worse psychiatric symptoms.

Saved in:
Bibliographic Details
Published inBrain, behavior, and immunity Vol. 62; pp. 41 - 45
Main Authors Severance, Emily G, Gressitt, Kristin L, Stallings, Cassie R, Katsafanas, Emily, Schweinfurth, Lucy A, Savage, Christina L.G, Adamos, Maria B, Sweeney, Kevin M, Origoni, Andrea E, Khushalani, Sunil, Dickerson, Faith B, Yolken, Robert H
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier Inc 01.05.2017
Subjects
Adolescent
Adult
Aged
Allergy and Immunology
Antibodies, Bacterial - isolation & purification
Autism
Candida albicans - immunology
Female
Fungus
Gastroenterology
Gastrointestinal Microbiome - drug effects
Gastrointestinal Tract - microbiology
Humans
Infection
Longitudinal Studies
Male
Mental health
Middle Aged
Pilot Projects
Probiotics - administration & dosage
Psychiatry
Schizophrenia - microbiology
Sex differences
Treatment Outcome
Young Adult
Infection
Fungus
Autism
Sex differences
Gastroenterology
Mental health
Online AccessGet full text

Cover

More Information
Summary:Highlights • In schizophrenia, elevated Candida yeast antibody levels were lowered by probiotics. • Probiotics compared to placebo also relieved yeast-related bowel discomfort over time. • Candida albicans seropositivity was associated with worse psychiatric symptoms.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-News-1
ObjectType-Feature-3
content type line 23
ISSN:0889-1591
1090-2139
DOI:10.1016/j.bbi.2016.11.019